AI-generated · cited to primary sources · not investment advice
Anthem Bioscienc (544449) May 2026 Filing Analysis
Does management do what it says?
The company is actively scouting for strategic acquisitions in India and abroad.
“Secondly, in terms of acquisitions and growth, apart from our organic growth, which is also substantive, we are not averse to looking at acquisitions, both in India and abroad. We are actively searching.”
A biosimilar asset currently in progress is expected to impact the P&L in the next financial year. — target: P&L Impact (+3 more commitments)
“I think, which will hit our P&L next year. Where will we classify it? I think it will go in CRDMO.”
See the full cited Management analysis of Anthem Bioscienc
How durable is the business?
Backward integration for a key intermediate has been completed, which is expected to protect and improve gross margins in future quarters. (5 expanding)
“We source the raw material, manufacture the intermediates, manufacture the API and supply to the customer, and we are not reliant on any external source. The backward integration had helped us in terms of improving our material margins.”
Capacity expansion is progressing with 54 kiloliters added in Q1 FY26. Total custom synthesis expansion of 134 kiloliters is on track for completion this calendar year. (5 expanding)
“Unit 4 is going to be much larger than all the units put together... This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation... We are more or less doubling on custom synthesis and adding 50% more on the fermentation side.”
The Specialty Ingredients segment continues to grow at a healthy pace (19.7% YoY), though its share of total revenue has slightly decreased due to the explosive growth in CRDMO. (5 expanding across 1 engine)
“Specialty ingredients delivered Rs. 98 crores, a growth of 8% YoY... Specialty ingredients contributed 17% to our revenue.”
Revenue for Specialty Ingredients was INR 87.5 crores. Management noted that while CRDMO is the primary driver, Specialty Ingredients help utilize capacity while client products await approval. (1 stable, 2 expanding across 1 engine)
“CRDMO 83.9% Q4FY26 Revenue Split... CRDMO business delivered ₹5,128 Mn revenues”
The company possesses deep technical expertise in complex modalities like peptides, oligonucleotides, and Antibody-Drug Conjugates (ADCs), which are difficult for competitors to replicate.
“Anthem has capability to do work in all these areas [peptides, oligonucleotides, and ADCs]. Because these are the new modalities and these are new areas of research... Anthem addresses all the problems through, find solutions, technological solutions.”
See the full cited Business Model analysis of Anthem Bioscienc
Where does growth come from?
Expansion is accelerating with the recent commissioning of the CP7 block in Unit-2 and ongoing civil work for the massive Unit-4 facility, which is expected to see major capital outflow by March 2027. (1 accelerating, 1 new trend, 3 steady across 5 signals, 2 leading indicators)
“In Phase 1 of that expansion, and we are looking at investing almost about Rs. 1,200 odd crores across two years... This will add close to about 365 kiloliters of custom synthesis capacity and 100 kiloliters of fermentation vis-à-vis our current capacity which is 425 kiloliters custom synthesis and 180 kiloliters fermentation.”
The number of commercial molecules has increased from 10 at the time of IPO to 14 currently, representing a 40% growth in the commercial portfolio. (3 accelerating, 2 steady across 5 signals)
“the current contribution from these four molecules will be in the range of closer to about 8% to 9% of our revenues... It takes two to three years to build to have the ramp-up.”
Capacity expansion is accelerating with the commissioning of 54 KL at Unit II and the phased commencement of Unit III, including specialized peptide and hi-potent facilities. Construction on the 30-acre Unit IV greenfield site has also begun. (1 accelerating, 1 steady across 2 signals, 1 leading indicator)
“we do a variety of payloads, at least I think 15 - 20 payloads we work on... that's a very interesting area and we have a huge amount of activity going on there.”
EBITDA margins are showing an accelerating trend, reaching 44.5% in the most recent quarter, up significantly from 40.4% a year ago and 38.1% in the preceding quarter. (4 accelerating, 1 decelerating across 5 signals, 1 leading indicator)
“Net Cash (₹ Mn) 12,312 (Dec 31, 2025) 13,743 (Mar 31, 2026)”
The contribution from new commercial molecules is in an early ramp-up phase. While currently small, management estimates the peak market potential for these four molecules at $10 billion. (1 new trend across 1 signal)
“Now we are in conversations with I would say all the big players to give them an alternate, which is based here in India. We're in a very good position as far as GLP-1 goes... That could happen in six months, it could happen in eight months.”
See the full cited Future Growth analysis of Anthem Bioscienc
What could break the thesis?
The company's net cash position has significantly improved to ₹9,934 Mn as of Sept 30, 2025, up from ₹7,848 Mn in the previous quarter, providing a larger buffer for upcoming capital expenditures. (1 easing, 4 stable, 2 high-severity)
“In Phase 1 of that expansion, and we are looking at investing almost about Rs. 1,200 odd crores across two years, this year FY27 and in FY28. We aim to complete the Phase 1 expansion by March '28 financial year... Unit 4 is going to be much larger than all the units put together.”
The risk is intensifying due to increased political rhetoric regarding drug pricing and potential US tariffs, though management believes their European supply route provides a buffer. (5 intensifying)
“the net expense recognized in "Exceptional Item" amounts to Rs. 243.91 million in the Consolidated financial results... arising due to change in wage definition and gratuity provisions.”
Specialty Ingredients revenue declined 13.1% YoY and 10.7% QoQ, confirming the volatility and potential crowding out by the dominant CRDMO segment. (2 intensifying, 2 easing, 1 stable)
“Q4FY26 Revenue Split: CRDMO 83.9%”
The risk is stable; management acknowledges the need to compete with China, particularly in the emerging GLP-1 space where they aim to be a leading producer. (2 stable, 1 resolved)
“In Korea particularly and in China also, the large companies have built up massive capacities. In that sense, they are ahead of us. There's no denying that. Because there is the upfront investment in large molecules is quite large, so you must be willing to invest billions of dollars for those kinds of capacities.”
See the full cited Risk analysis of Anthem Bioscienc
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.